Date: 2014-07-03
Type of information: Licensing agreement
Compound: AAV-DJ, proprietary serotype of AAV (Adeno-Associated Virus)
Company: Horizon Discovery (UK), Stanford University (USA - CA)
Therapeutic area: Technology - Services
Type agreement: licensing
Action mechanism: Created by Professor Mark Kay at Stanford this artificial serotype of AAV known as AAV-DJ effectively transduces (infects) a broader range of mammalian cells (>80%) than any naturally occurring AAV serotype, enabling Horizon to target an increased range of cell types. Combined with Horizon’s existing exclusive license for use of rAAV (recombinant Adeno-Associated Virus) from the University of Washington, the Company is the sole source of this effective and highly precise mechanism for gene editing.
Disease:
Details: * On July 3, 2014, Horizon Discovery™ Group, a leading provider of research tools to support translational genomics and the development of personalized medicines, announced it has entered into a non-exclusive license agreement with Stanford University to access intellectual property related to the use of a proprietary serotype of AAV (Adeno-Associated Virus) for commercial applications involving homologous recombination in gene editing. In February 2014 Horizon announced the launch of its GENASSIST™ range of gene editing kits and reagents that enable easier, robust implementation of CRISPR and rAAV gene editing experiments. The current GENASSIST offering comprises both off-the-shelf reagents for using CRISPR editing technology and a unique kit combination of these reagents to allow customers to generate their own CRISPR-ready cell lines that constitutively express Cas9-nickase.
Financial terms:
Latest news:
